Study guide
4.6 SOS/VOD Diagnostic Criteria, Surveillance & Defibrotide Therapy
Transplantation and Cellular Therapy Certified Nurse TCTCN
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 The TCTCN Credential: Rename, Scope & Official Test Blueprint 1.2 TCTCN Eligibility, Test-Day Logistics, Scoring & Renewal 1.3 Building the Study Plan & Clinical Prioritization Framework 1.4 Clinical Triage Rehearsal & Exam-Day Question Strategy
2 Chapter 2: Foundations of Transplantation & Cellular Biology
2.1 Hematopoietic Lineage, the MHC & HLA Class I vs Class II Biology 2.2 HLA Typing Resolution, Donor Matching, DSA & ABO Compatibility 2.3 Disease Indications & the Cellular Therapy Modality Map 2.4 Pre-Transplant Risk Stratification & Organ Suitability Assessment 2.5 Stem Cell & Cellular Product Sources: Donor Selection Hierarchy 2.6 Conditioning Regimens & Lymphodepletion Principles 2.7 Recipient and Caregiver Education Across the Continuum
3 Chapter 3: Product Collection, Processing & Infusion Procedures
3.1 Stem Cell Mobilization: Niche Biology, Agents & CD34+ Collection Targets 3.2 Apheresis Nursing Care: Vascular Access, Citrate Toxicity & Donor Safety 3.3 Graft Engineering, ABO-Directed Processing & Cryopreservation Science 3.4 DMSO Toxicity, Premedication & Time-Critical Thawed Product Administration 3.5 Pre-Administration Verification, Equipment & CAR T Infusion Readiness 3.6 Infusion Monitoring & Acute Reaction Differential Management 3.7 Engraftment Definitions, Kinetics & Factors Impairing Recovery 3.8 Graft Failure Classification & Donor Chimerism Tracking
4 Chapter 4: Acute Post-HSCT Complications & Graft-versus-Host Disease
4.1 Acute GVHD: Billingham's Postulates, Classification & the Ferrara 3-Phase Model 4.2 Acute GVHD Organ Manifestations, Histopathology & MAGIC Staging 4.3 MAGIC Overall Grading & Acute GVHD Plasma Biomarkers 4.4 Acute GVHD Prophylaxis, First-Line Steroids & Steroid-Refractory Therapy 4.5 SOS/VOD: Microvascular Pathophysiology & Risk Stratification 4.6 SOS/VOD Diagnostic Criteria, Surveillance & Defibrotide Therapy 4.7 TA-TMA: Complement Pathophysiology, Harmonized Criteria & Differential 4.8 TA-TMA Management, Complement-Directed Therapy & Other Endothelial Syndromes
5 Chapter 5: Post-Transplant Infections & Supportive Care
5.1 Neutropenic Fever, Pre-Engraftment Phase & Empiric Antimicrobial Therapy 5.2 CMV: Risk Stratification, Letermovir Prophylaxis & DNAemia Treatment 5.3 EBV/PTLD, HHV-6 Encephalitis, BK Cystitis, Adenovirus, HSV & VZV 5.4 Invasive Fungal Infections (Aspergillus, Candida, Mucor) & PJP Prophylaxis 5.5 Supportive Care in Aplasia: Transfusion Guidelines, Oral Mucositis & Nutrition
6 Chapter 6: Post-Cellular Therapy Management, CRS & ICANS
6.1 CAR Structural Architecture, Generations & Costimulatory Domain Biology 6.2 The Vein-to-Vein Lifecycle, In Vivo Kinetics & On-Target B-Cell Aplasia 6.3 CRS Pathophysiology, Clinical Kinetics & Inflammatory Biomarkers 6.4 ASTCT CRS Grading, Tocilizumab & Escalation Management 6.5 ICANS: Assessment, ICE Scoring & Clinical Management 6.6 Delayed Cellular Toxicities: Prolonged Cytopenias, B-Cell Aplasia & IEC-HS 6.7 Symptom Management and Functional Recovery After Cellular Therapy
7 Chapter 7: Chronic GVHD & Long-Term Survivorship
7.1 Chronic GVHD: Three-Phase Immunobiology & NIH Classification 7.2 Chronic GVHD Diagnostic Manifestations, BOS & NIH Global Severity Scoring 7.3 Chronic GVHD: Systemic, Steroid-Sparing & Multidisciplinary Therapy 7.4 Late Effects: Endocrine, Cardiovascular, Bone Health & Secondary Malignancies 7.5 Immune Reconstitution & the Inactivated Re-Vaccination Schedule 7.6 Live Vaccines, Household Contact Precautions & Survivorship Care Plans 7.7 Post-HSCT Relapse: Surveillance, Immunologic Manipulation & Treatment
8 Chapter 8: Quality of Life, Ethics & Professional Practice Standards
8.1 Psychosocial Trajectories, Distress Screening & Delirium Assessment 8.2 Caregiver Planning, Financial & Cultural Navigation, and Sexual Health 8.3 Palliative Care Integration, Advance Directives & Ethical Considerations 8.4 FACT-JACIE Quality Standards, CIBMTR / NMDP Reporting & Compliance 8.5 Evidence-Based Practice, Discharge Education & Quality Improvement
4.6 SOS/VOD Diagnostic Criteria, Surveillance & Defibrotide Therapy
Key Takeaways Explain This Topic AI
Baltimore, modified Seattle, and adult/pediatric EBMT criteria differ in timing and bilirubin requirements; pediatric and late-onset disease can be anicteric.
Trend weight, fluid balance, abdominal/liver findings, bilirubin, renal/pulmonary status and platelet consumption using the program surveillance plan; no one imaging sign replaces clinical criteria.
Supportive care limits additional hepatic injury and manages fluid/organ complications while avoiding nephrotoxins and unsafe fluid removal.
Defibrotide is FDA-approved for hepatic VOD/SOS with renal or pulmonary dysfunction after HCT. Use 6.25 mg/kg IV every 6 hours per label for at least 21 days, continuing until resolution or 60 days maximum; monitor bleeding and contraindicated systemic anticoagulant/fibrinolytic therapy.
Last updated: September 2026
1. Diagnostic Criteria Frameworks: Baltimore, Seattle & EBMT
Because liver biopsy carries severe bleeding risks in thrombocytopenic transplant recipients, SOS/VOD is primarily a clinical syndromic diagnosis based on validated scoring frameworks. +---------------------------------------------------------------------------------------------------+
- | SOS / VOD DIAGNOSTIC CRITERIA COMPARISON |
- | |
- | MODIFIED SEATTLE CRITERIA (Within Day +20): |
- | Requires at least 2 of the following 3 features: |
- | 1. Hyperbilirubinemia (Total Bilirubin >= 2.0 mg/dL / 34 µmol/L) |
- | 2. Hepatomegaly (usually painful) OR Right Upper Quadrant (RUQ) Pain |
- | 3. Unexplained Weight Gain >= 2% from baseline due to fluid retention |
- | |
- | BALTIMORE CRITERIA (Within Day +21): |
- | MANDATORY: Hyperbilirubinemia (Total Bilirubin >= 2.0 mg/dL / 34 µmol/L) |
- | PLUS at least 2 of the following: |
- | 1. Painful Hepatomegaly |
- | 2. Ascites |
- | 3. Weight Gain >= 5% from pre-conditioning baseline |
- | |
- | EBMT UPDATED CRITERIA (Adults & Pediatrics): |
- | * Classical SOS: Onset <= Day 21 |
- | * Late-Onset SOS: Onset > Day 21 (common with RIC, busulfan PK, or inotuzumab) |
- | * Pediatric Criteria: Does NOT require hyperbilirubinemia (allows diagnosis in anicteric cases)!|
- +---------------------------------------------------------------------------------------------------+
- Detailed Diagnostic Criteria Comparison Table
Diagnostic System Timing Threshold Bilirubin Requirement Weight Gain Threshold Additional Mandatory / Optional Criteria
Modified Seattle Within Day +20 post-HCT >= 2.0 mg/dL (34 µmol/L) (as 1 of 3 criteria) >= 2% above pre-transplant baseline Requires at least 2 of 3 criteria: Bilirubin >= 2.0, Weight gain >= 2%, or Hepatomegaly / RUQ pain.
Baltimore Within Day +21 post-HCT MANDATORY: >= 2.0 mg/dL (34 µmol/L) >= 5% above pre-transplant baseline Requires Bilirubin >= 2.0 PLUS at least 2 of: Hepatomegaly, Ascites, or Weight gain >= 5%.
EBMT adults Classical <=21 d or late-onset >21 d Classical criteria require bilirubin >=2.0 mg/dL >5% is one feature Classical: bilirubin plus 2 of painful hepatomegaly, weight gain >5%, or ascites. Late-onset: classical criteria, histologic proof, or at least 2 SOS features plus hemodynamic/ultrasound evidence.
EBMT pediatrics No fixed day limit Hyperbilirubinemia is not required; a rising pattern is one feature Persistent unexplained gain despite diuretics or >5% is one feature At least 2 pediatric features: consumptive/transfusion-refractory thrombocytopenia, qualifying weight gain, hepatomegaly, ascites, or qualifying bilirubin rise. Apply the complete pediatric definition.
2. Management and Defibrotide
Immediately review conditioning and hepatotoxic exposures, avoid additional liver injury where possible, manage sodium/fluid balance with frequent reassessment, and support renal, pulmonary, coagulation, and hemodynamic complications. Diuresis, paracentesis, renal replacement, or critical-care support depends on physiology; an arbitrary fluid cap is unsafe.
Defibrotide (Defitelio) is FDA-approved for hepatic VOD/SOS with renal or pulmonary dysfunction after HCT. The labeled dose is 6.25 mg/kg IV every 6 hours, infused over 2 hours, based on pre-conditioning baseline weight. Treat for at least 21 days; if signs and symptoms persist, continue until resolution or a maximum of 60 days. Do not initiate in active bleeding, discontinue for significant bleeding, and do not give with systemic anticoagulant or fibrinolytic therapy except routine central-line maintenance addressed by the label. Hold around invasive procedures according to the prescribing information and program plan. Defibrotide can cause hemorrhage; it does not provide bleeding-free fibrinolysis.
Loading diagram... SOS/VOD Recognition and Management
- 3. Diagnostic Workup and Hemodynamic Assessment
- Imaging
Doppler ultrasonography can support the assessment and help evaluate biliary obstruction, vascular flow, ascites and other competing causes. Findings such as hepatomegaly, ascites, gallbladder-wall edema, altered portal flow or hepatic-artery indices are neither uniformly present nor independently diagnostic. Interpret them with timing, serial weight/fluid balance, bilirubin trajectory, platelet consumption and organ dysfunction.
When the diagnosis remains uncertain, specialist-selected testing may include advanced ultrasound scoring, elastography, hemodynamic assessment or transjugular biopsy. The hepatic venous pressure gradient is calculated as wedged hepatic venous pressure minus free hepatic venous pressure . Elevated gradients can support portal hypertension/SOS, but no invasive result replaces the complete clinical framework. A transjugular approach may lower peritoneal bleeding risk compared with percutaneous biopsy; it does not eliminate hemorrhage or sampling risk.
4. Defibrotide Safety Translation
Use the current label-directed regimen and transplant order set. Before every dose, review bleeding, concomitant systemic anticoagulant/fibrinolytic therapy, planned procedures, line compatibility and product preparation/expiration. A central-line maintenance flush is handled according to the specific label and program; it is not permission for therapeutic anticoagulation. Stop and escalate significant bleeding or hypersensitivity and document response across bilirubin, weight/fluid status and renal/pulmonary dysfunction.
5. Bedside Surveillance and Supportive Care
Obtain same-scale weights and accurate intake/output at the center’s ordered frequency; trend abdominal girth, ascites, right-upper-quadrant pain and respiratory status.
Trend bilirubin/liver tests, creatinine, urine output, oxygen need, blood counts, coagulation and transfusion response. Do not use one platelet or fibrinogen goal for every patient.
Provide patient-specific sodium/fluid management and diuresis while protecting renal perfusion. Review nephrotoxic and hepatotoxic drugs with the team rather than stopping essential therapy independently.
Escalate rapid weight gain, falling urine output, increasing oxygen need, hypotension, bleeding, confusion or other multiorgan dysfunction promptly.
6. Managing Bleeding Risk During Defibrotide Therapy
Defibrotide's profibrinolytic and endothelial-protective activity is inseparable from its bleeding risk, and the therapy runs for weeks in a patient who is already thrombocytopenic, which makes bleeding surveillance a continuous nursing responsibility rather than an admission check.
Concurrent systemic anticoagulant or fibrinolytic therapy is contraindicated, so the medication list is reviewed at initiation and whenever a new order is written. Prophylactic anticoagulation ordered by another service is a real and recurring hazard.
Therapy is interrupted around bleeding and procedures. Clinically significant bleeding requiring intervention prompts holding the drug, and doses are withheld before invasive procedures and resumed afterward according to the label and the ordering team. Nurses are frequently the first to know a procedure has been scheduled, so surfacing it early prevents a dose given at the wrong time.
Surveillance is systematic. Assess mucosal surfaces, catheter exit sites, urine, stool, sputum, and neurologic status each shift; trend hemoglobin and platelets against transfusion history rather than in isolation; and treat a new headache, altered mental status, or unexplained hemoglobin drop as potential bleeding until evaluated.
Bedside care reduces avoidable trauma. Use soft oral care, avoid rectal medications and temperatures, minimize venipuncture, hold pressure longer than usual, and coordinate line care with the platelet count.